Stan Louie, PharmD

Dr. Louie is a translational pharmacologist with expertise in advancing hit candidates through preclinical development and into clinical evaluation. His drug discovery strategies is to use metabolomics/lipidomics to identify drug targets. His team has developed four therapeutic modality from benchtop to clinical evaluation. His area of focus include inflammation and development of drug that promote regenerations.

• March of Dimes Research Fellowship, 1979
   – 1982
• Rho Chi Honor Society, 1985
• Paper of the Year Award, 1997
• California Society of Health System Pharmacist: Fellow, 1998
• American Society of Health System Pharmacists: Fellow, 2000

• Drug Development for Alzheimer's neuroinflammation
  NIH · U01AG094622 · Aug 1, 2025 – Jul 31, 2030 · Role: Co-Principal Investigator
• NorLeu3Angiotensin (1-7) Promotes Non-Fibrotic Healing in Ocular Globe Injury Models
  Department of Defense · Sep 1, 2021 – Aug 31, 2024
• Molecular Mechanism of Drug Resistance in Obese Leukemic
  National Cancer Institute · Jul 1, 2017 – Jun 30, 2022

• Inflammation, RAS, Specialize Lipid Mediators

• Lenz, Heinz-Josef
• Hamm-Alvarez, Sarah
• Bernstein, Kenneth
• Yassine, Hussein
• MacKay, John
• Armstrong, David